This article originally appeared on Undark.
When chatting at cocktail parties about his job, Mark Ratain, an oncologist and pharmacologist at the University of Chicago, often asks a short riddle: Your doctor gives you a prescription for a new drug. The pharmacist says, Make sure you take it on an empty stomach, twice a day. What do you think would happen if you took it with food?
Most don t get the answer right. Nobody would ever say, Well, I could die from an overdose, Ratain says.
Advertisement:
That s exactly what could happen to anyone taking the drug nilotinib approved by the U.S. Food and Drug Administration in 2007 to treat the blood cancer chronic myelogenous leukemia. The drug is among the most effective cancer therapies; a patient taking it may have a 96 percent chance of surviving the cancer for at least six years, according to one of the most recent long-term studies. But the FDA-approved label for nilotinib carries a black box warning: Take it on an empty s
Molecular Partners Announces New Clinical Data, Immunomodulation Platform Advances, and Virology Portfolio Strategy
albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.
Molecular Partners Announces New Clinical Data, Immunomodulation Platform Advances, and Virology Portfolio Strategy
First-in-human data from ongoing phase 1 study of MP0310 (AMG 506) demonstrate encouraging biological activity, including successful localized tumor engagement and saturation
Data from ongoing phase 1 COVID-19 study show that MP0420 (ensovibep) is well tolerated in first dose cohort
Unique immunomodulation platforms advanced to readiness for candidate generation using CD-3 T cell engagers and pMHC binders
Virology portfolio launched with focus on major global viral threats where unique DARPin® therapeutic profile could make major impact
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / December 17, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced multiple advances across clinical and preclinical programs, as well as an expansion of it
(2)
First-in-human data from ongoing phase 1 study of MP0310 (AMG 506) demonstrate encouraging biological activity, including successful localized tumor engagement and saturation
Data from ongoing phase 1 COVID-19 study show that MP0420 (ensovibep) is well tolerated in first dose cohort
Unique immunomodulation platforms advanced to readiness for candidate generation using CD-3 T cell engagers and pMHC binders
Virology portfolio launched with focus on major global viral threats where unique DARPin® therapeutic profile could make major impact
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / December 17, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced multiple advances across clinical and preclinical programs, as well as an expansion of its corporate strategy to develop a portfolio of therapies targeting global viral threats. These advances will be de
email article
The mRNA-based vaccines for COVID-19 not only offer hope for bringing the pandemic under control but a glimpse into the future of new therapies for cancer and other chronic diseases. (
Bloomberg)
Members of the American Society of Clinical Oncology elected Eric Winer, MD, of Dana-Farber Cancer Institute in Boston, as president for 2022-23.
The chemotherapy-free combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) improved overall survival, progression-free survival, and objective response rate in a phase III trial of advanced endometrial cancer, Merck announced.
The incidence of esophageal adenocarcinoma is increasing in people younger than 50. (
American Association for Cancer Research)
vimarsana © 2020. All Rights Reserved.